Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared on X:
“Does adding nivolumab to deb-TACE improve outcomes in liver-limited HCC?
Phase I (n=19): ORR 21%, PFS 5.9mo, OS 23mo, no better than deb-TACE alone.
Well tolerated; no treatment-related deaths.”
Title: A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma
Authors: J.J. Harding, O.M. Fitzpatrick, J.F. Chou, H. Yarmohammadi, K.A. Reiss, R.K. Do, P. Wong, D.N. Khalil, I. El Dika, C. Ferrer, O. Heffernan, A. Yaqubie, J.D. Giardina, M. D’Angelica, W.R. Jarnagin, G. Nadolski, A. Covey, J.P. Erinjeri, K. Brown, M.C. Soulen, B. Tan, M. Capanu, G.K. Abou-Alfa
Read the Full Article
You can also read: ‘TALENTOP: Liver Resection After Atezolizumab and Bevacizumab in Locally Advanced HCC‘
